Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.…
Nephros (NEPH) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Nephros (NASDAQ: NEPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 36 employees.
The shares were at 2.610 USD on 20 November 2026, down 43.3% over 52 weeks. Its 52-week range is 2.610 USD to 6.420 USD, and it trades at the bottom of that range.
At a market capitalisation of 28.37M USD, it trades at 15.4 times trailing earnings and 11.9 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 68% for NEPH.
Nephros reports return on equity of 11.7%, an operating margin of 8.5% and revenue up 18.0% year over year.
It holds more cash than debt, a net cash position of 3.77M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 6.083 USD is 133.1% above the current price. The next earnings report is expected on 11 March 2027.